Next Article in Journal
Discrepancy between the Status Quo and Adjusted Risk of First-Onset Suicidal Ideation in Older Adults: A Longitudinal Study Based on the Korean Welfare Panel Study (2011–2021)
Next Article in Special Issue
Turbo Gradient and Spin-Echo BLADE-DWI for Extraocular Muscles in Thyroid-Associated Ophthalmopathy
Previous Article in Journal
Relationship between Residual Urine Output and Type of Dialysis with FGF23 Levels
Previous Article in Special Issue
A Framework of Analysis to Facilitate the Harmonization of Multicenter Radiomic Features in Prostate Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 12
Issue 1
10.3390/jcm12010223
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Targeting Copper in Cancer Imaging and Therapy: A New Theragnostic Agent

by
Gabriela Capriotti
1,*,
Arnoldo Piccardo
2,
Elena Giovannelli
1 and
Alberto Signore
1
1
Department of Medical-Surgical Sciences and of Translational Medicine, Sapienza University of Rome, Nuclear Medicine Unit Sant’Andrea University Hospital, 00189 Rome, Italy
2
S.C. Medicina Nucleare Ente Ospedaliero “Ospedali Galliera”, 16128 Genova, Italy
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2023, 12(1), 223; https://doi.org/10.3390/jcm12010223
Submission received: 22 November 2022 / Revised: 20 December 2022 / Accepted: 22 December 2022 / Published: 28 December 2022
(This article belongs to the Special Issue 10th Anniversary of JCM - Nuclear Medicine & Radiology)
Browse Figures
Review Reports Versions Notes

Abstract

:
Copper is required for cancer cell proliferation and tumor angiogenesis. Copper-64 radionuclide (64Cu), a form of copper chloride (64CuCl2), is rapidly emerging as a diagnostic PET/CT tracer in oncology. It may also represent an interesting alternative to gallium-68 (68Ga) as a radionuclide precursor for labelling radiopharmaceuticals used to investigate neuroendocrine tumors and prostate cancer. This emerging interest is also related to the nuclear properties of 64CuCl2 that make it an ideal theragnostic nuclide. Indeed, 64CuCl2 emits β+ and β- particles together with high-linear-energy-transfer Auger electrons, suggesting the therapeutic potential of 64CuCl2 for the radionuclide cancer therapy of copper-avid tumors. Recently, 64CuCl2 was successfully used to image prostate cancer, bladder cancer, glioblastoma multiforme (GBM), and non-small cell lung carcinoma in humans. Copper cancer uptake was related to the expression of human copper transport 1 (hCTR1) on the cancer cell surface. Biodistribution, toxicology and radiation safety studies showed its radiation and toxicology safety. Based on the findings from the preclinical research studies, 64CuCl2 PET/CT also holds potential for the diagnostic imaging of human hepatocellular carcinoma (HCC), malignant melanoma, and the detection of the intracranial metastasis of copper-avid tumors based on the low physiological background of radioactive copper uptake in the brain.

1. Introduction

Currently, basic imaging modalities, such as single photon emission computed tomography (SPECT), positron emission tomography (PET), magnetic resonance imaging (MRI), computed tomography (CT), optical imaging, ultrasound imaging, etc., are regularly used to evaluate specific targets in clinical settings. Among various molecular imaging modalities, the growth of PET imaging has been particularly important over the past decade. PET imaging provides the possibility to evaluate living systems using positron emitting radioisotopes with high sensitivity and specificity. This imaging modality can improve decision making and select only the right patients for tailored therapeutic regimens [1]. A crucial node in molecular imaging with PET is the development of specific radiopharmaceuticals and the choice of the radionuclide to obtain a PET probe, which correlates with its chemical and physical characteristics and feasibility of production. Therefore, copper radionuclides are being studied for both molecular imaging and therapy and many efforts have been made to evaluate the clinical potential of copper radiopharmaceuticals.

2. Nuclear Copper and Properties

Research is focused on five of the 32 copper isotopes—60Cu, 61Cu, 62Cu, 64Cu, and 67Cu—that have the necessary characteristics to be used in the clinical setting (Table 1) [2]. The most studied and promising of these isotopes appears to be 64Cu. This isotope decays with the emission of a low-energy positron (650 keV) with shallow average penetration into tissues, that makes this isotope fit for diagnostic PET images with significantly high resolution.
64Cu decays through three different routes, namely, electron capture (EC, 42.5%), β− (38%; Eb- 190keV) and β+ (19%; Eb- 278keV) decay [Table 1]. Furthermore, 64Cu emits Auger electrons. These features make this isotope a pure theragnostic agent [1,3]. The decay characteristics of 64Cu allows for PET images that are comparable in quality to those obtained using 18F, while the longer half-life (12.7h) of 64Cu and its chemical versatility allow for the preparation of many radiopharmaceuticals using different molecules, peptides, proteins and nanoparticles.
64Cu can be produced via multiple routes. The most recent approach for the production of copper-64 is by nuclear reactor, which appears to be the most suitable option for regular use in a clinical setting [4]. Cyclotron production is also commonly used. 64Ni particles are irradiated with low-energy neutrons, leading to the production of 64Cu in the form of [64Cu] CuCl2, with high purity [3,5].
Regardless of the method of production, 64Cu has been used in preclinical and clinical studies that have demonstrated that, in its simple ionic form, it highly accumulates in multiple tumors [5]. In recent years, several studies regarding the use of novel radiopharmaceuticals labelled with 64Cu have been published.

3. Biological Role of Copper as Theragnostic Agent

Copper is an essential nutrient in mammals, acting as a cofactor in the normal functioning of many physiological processes. It plays an important role in angiogenesis and can stimulate endothelial cell proliferation in a variety of benign and malignant situations. The cellular distribution of copper is rather complex, and although the exact mechanisms by which copper is internalized by human cells are not yet completely clarified, recent data indicate that copper in its ionic form (Cu2+) is rapidly bound to plasma proteins in the blood stream (albumin, ceruloplasmin, transcuprein) and reaches the cell surface, where Cu2+ ions are reduced to Cu+ by specific enzymes called reductases [3,6,7]. Reduced copper enters in the cell through the human copper transporter 1 (hCTR1) [2] and binds to the tri-peptide glutathione (GSH), acting as primary copper acceptor. GSH plays a safeguarding role by binding excess Cu+ ions, to prevent oxidative damage due to redox cycling, thus protecting the cell from copper toxicity [8,9]. After this first phase, copper ions are handed off to copper chaperones and proteins (cytochrome c oxidase copper chaperone (COX17), copper chaperone for SOD1 (CCS), and antioxidant protein (ATOX1)), thus keeping them in a bound Cu+ state by preventing redox cycling. These chaperones deliver Cu+ ions to cytosolic SOD1, cytochrome c oxidase (COX) in the mitochondria and copper transporting ATPase A/B (ATP7A/B) at the trans-Golgi network (TGN), respectively (Figure 1). Analogous mechanisms are carried out by metallothioneins capable of irreversibly binding Cu+ ions. When intracellular copper exceeds a certain level, hCTR1 is internalized and destroyed. During this process, copper transporting ATPase A/B (ATP7A and ATP7B) transfer from the TGN to the plasma membrane to help in the excretion of copper from the cell [3,10]. Copper is mainly stored and redistributed by the liver, and thus the hepatobiliary system appears to be the principal means of elimination of excess copper ions [5].
Copper ions play an essential role in several biological processes, and copper is a cofactor of many enzymatic reactions, a structural component of different proteins and a key modulator of cell proliferation and growth. Preclinical and clinical studies have demonstrated that copper is deeply involved in the development, growth and progression of malignant lesions. Experimental data have shown significant differences in copper metabolism between normal and cancerous cells. Some of these studies have revealed a significantly higher expression of hCTR1 in malignant tissues than normal tissues, including prostate cancer, lung cancer, glioblastomas, liver cancer, breast cancer, and melanoma [5,11]. Furthermore, copper in its simple ionic form is mostly located in the cytosolic fraction of normal cells, while in tumor cells, these ions mainly diffuse to the nuclear and perinuclear space [3,5]. Therefore, it was hypothesized that hCTR1 could be used as a target for molecular imaging of a wide variety of cancers [8,9,12]. Several researchers have reported an elevated level of copper uptake in malignant tissues [4], such as prostate cancer, lung cancer, breast and liver cancer, glioblastoma and melanoma, and it was proposed that hCTR1 could be used to visualize a large number of tumors [9].
An increased copper concentration in the neoplastic cells could be easily evaluated in vivo using radioactive copper (64Cu2+) ions as radiopharmaceutical. Indeed, 64Cu2+ ions can serve as an effective biomarker for the noninvasive assessment of cancer, using PET imaging. Many mouse animal models of a wide variety of cancers, such as prostate, lung, breast, ovarian, colorectal, brain and head and neck cancer, hepatoma, fibrosarcoma and melanoma, have been used to explore the biodistribution and uptake of 64Cu as a diagnostic or therapeutic agent [9]. Mouse copper transporter receptor 1 (mCTR1) plays the same role as hCTR1 in the intracellular transport of radioactive copper in animal models [9]. PET imaging and biodistribution studies demonstrated the correlation between tumor uptake of 64Cu and the level of mCTR1 assessed by immunohistochemistry techniques [4]. Furthermore, preliminary results confirmed that 64Cu is selectively concentrated in malignant tissue and not in inflammatory tissues, suggesting the potential role of this radionuclide as a specific tumor marker and its use as a theragnostic agent.

4. Cancer Imaging

As mentioned before, copper is a transitional metal required for the function of many molecules involved in human processes [13,14] and in signaling transduction pathway regulating cancer cell proliferation and tumor growth [15,16,17], giving rise to the possibility to use it for metabolic PET imaging [18,19]. A high intracellular concentration of copper is allowed by an elevated expression of hCTR1, and reduced tumor 64Cu uptake and tumor growth inhibition caused by RNA-mediated hCTR1 knockdown have been shown, suggesting that hCTR1 is a promising novel theragnostic target. Some clinical and preliminary human studies have strongly supported these preclinical observations.
A pilot study was carried out by Capasso E. et al. to evaluate the possible role of 64Cu-PET in the staging of patients with prostate cancer (PCa) [20]. Seven patients with PCa were prospectively enrolled, and three patients underwent adrenal deprivation. The remaining patients underwent no therapy. The authors found prostate cancer lesions in the pelvic area, thanks to the absence of urinary excretion of 64CuCl2. Uptake was higher in the primary tumors of patients without ADT than in treated patients, while the nodal uptake was variable, with focal concentration in normal size node and no significant uptake in suspected lymphadenopathy. These preliminary results indicate the potential role of 64Cu-PET for the diagnosis of PCa.
Subsequently, Piccardo A. et al. prospectively evaluated the biodistribution, dosimetry and lesion kinetics in 50 PCa patients with biochemical relapse after surgery or radiation therapy [21]. This study compared the diagnostic performance of 64Cu-PET/CT, 18F-choline PET/CT, and multiparametric MRI (mpMRI). The results showed the effectiveness of 64Cu-PET/CT in detecting local relapse along with bone and nodes metastases (Figure 2).
The detection rate (DR) of 64Cu-PET/CT was higher than the DR of 18F-choline PET/CT and multiparametric MRI, particularly in patients with biochemical relapse and a low PSA level [21]. The success of 64Cu-PET/CT can be related to the better biodistribution than 18F-choline PET/CT; copper ions are not eliminated via the kidneys and do not concentrate in the urinary tract, and this allows an accurate evaluation of the pelvic region and prostatic bed with early visualization of pelvic lesions. Furthermore, dosimetry studies showed that the dose absorbed by PCa recurrences and metastases is low, not considering the therapeutic effect of Auger electrons [22]. More recently, it has been demonstrated that 64Cu-PET/MRI shows a higher overall DR in the evaluation of PCa local recurrence than the DR of 18F-Choline PET/MRI, 64Cu-PET/CT, 18F-Choline PET/CT and mpMRI alone [23].
There are relevant findings on potential uses of 64CuCl2 PET/CT for the study of PCa, but Cantiello F et al. suggested that 64CuCl2 PET/CT presents some limitations and is not always able to overcome the current imaging methods in use for PCa [24]. In primary PCa staging, there are no differences between mpMRI and 64CuCl2 PET/CT in metastatic node detection, while in restaging, a significantly higher DR than for 18F-choline PET/CT in the lesion-based analysis both for local and lymph nodal staging can be observed, but not in the patient-based analysis. Furthermore, 64CuCl2 is mainly removed by the liver, and this could result in a failure to detect liver metastases.
Mascia M. et al. evaluated the safety and efficacy of 64CuCl2 as a PET radiopharmaceutical to image other urological malignancies [25]. In this prospective study, a total of 23 patients were enrolled, including patients with renal cancer, bladder and penile cancer. Obviously, PCa lesions showed the highest 64Cu uptake (SUVmax 11.5), while it was relatively high for bladder cancer (SUVmax 6.2) when compared to penile cancer (SUVmax 3.9) and renal cancer (SUVmax 5.0), suggesting that 64Cu-PET/CT might be useful to evaluate primary and local recurrent bladder cancer lesions in view of a high 64Cu target to background ratio. In contrast, a high background of 64Cu uptake in the kidneys (SUVmax 10.4) could limit its use for the evaluation of primary renal cancer lesions.
Another pilot study has been conducted by Panichelli P. et al. who evaluated the feasibility of 64CuCl2 PET/CT to image patients affected by glioblastoma (GBM) [26]. A high tumor uptake of 64Cu was observed in all patients affected by GBM, in contrast to the low tumor uptake of 64Cu in patients diagnosed with low-grade astrocytoma. Remarkably, in the same study, neoplastic tissue was rapidly and clearly detected with stable retention of radioactivity over time. This study provides further evidence to support using 64CuCl2 as a radiopharmaceutical for PET imaging (Figure 3).
Similar results were obtained by Fiz F. et al., who evaluated the distribution and dosimetry of 64CuCl2 dosimetry in pediatric patients affected by diffuse high-grade glioma [27]. 64Cu-PET/CT presents favorable dosimetry and helps to identify tumor relapses in patients that show unclear MRI results (contrast enhancement and necrosis).
García-Pérez FO et al. evaluated 64Cu uptake by non-small cell lung cancer in a limited cohort of patients [28]. The authors observed a high 64Cu uptake in peripheral large primary lung cancer lesion on PET/CT images, similar to FDG uptake. High uptake of 64Cu was detected in 36% of primary tumors and 27% of nodal metastases. Furthermore, the patients with high tumor uptake of 64Cu presented partial response to chemotherapy, while three patients with very low uptake of 64Cu displayed disease progression.
As said before, the 64Cu uptake is related to the expression of CTR1, thus selecting patients who may benefit from platinum-based therapy, because this transporter could be involved in cellular uptake or the retention of chemotherapy. So, 64Cu-PET/CT could be used to avoid ineffective platinum-based chemotherapy in the patients with non-64Cu-avid lung cancer lesions.

5. Theragnostic Aspect

64CuCl2 is currently the most actively investigated radiopharmaceutical for both diagnoses and therapy. It has recently been proposed as a promising agent for PCa theragnostics, based on preclinical studies in cells and animal models [29]. Guerreiro et al., using a panel of PC cell lines in comparison with a non-tumoral prostate cell line, performed cytogenetics and radio-cytotoxicity studies to obtain information about cellular consequences to the exposure of 64CuCl2. In this work, PCa cells were found to exhibit increased 64CuCl2 uptake, which could not be attributed to an over-expression of copper CTR1 with respect to non-tumoral cells. DNA damage and genomic instability were also high in PCa cells from patients and in tumoral cell lines, exhibiting deficient DNA-damage repair upon exposure to 64CuCl2.
Pinto C et al. evaluated the potential therapeutic effect in a mouse model of PCa [30]. 64CuCl2 has significant detrimental effects on cancer cells, being able to reduce their growth and impair the viability. Likewise, the potential theragnostic role of 64CuCl2 has been evaluated in GBM by Ferrari et al. [31]. The authors demonstrated that 64CuCl2 exhibits increased affinity for GBM cells than normal cells, thus supporting its potential role as a novel promising diagnostic PET probe for cerebral tumor imaging. Furthermore, their results on therapy suggest that this radiopharmaceutical has great potential as a therapeutic agent for GBM, as clearly shown by the survival curves in experiments carried out with single- and multiple-dose treatments. Catalogna G et al. evaluated the combined effects of 64CuCl2 and SI113, inhibitor of a serine/threonine protein kinase, on human GBM cell lines [32]. The authors demonstrate that the co-treatment with SI113 leads to synergistic effects on cell death.
At the end of this overview, one more aspect needs to be considered in relation to 64Cu ions as radiopharmaceuticals: is the copper toxic?
Some calculations show that, when used as a radiopharmaceutical, 64CuCl2 is not harmful to the patient. The total copper in the human body is about 100 mg and the daily dietary intake is about 1–2 mg. It has been reported that the cytotoxic effects of copper ions appear only at concentration ≥ 7.42 mg/L [33,34]. Considering this concentration as the threshold limit, cytotoxicity effects are not considered when using 64Cu for PET imaging, because for a PET study, 185–370 MBq of 64Cu is usually administered, equivalent to less than 100 µg of Cu2+ ions (being the specific activity of 64Cu 3.7 MBq/µg−1) [20]. In the case of therapy, a dose of 3700 MBq can be administered, being equivalent to 1 mg of Cu2+ ions, which is still below the toxicity threshold.
Righi S. et al. [22] demonstrated that the mean dose absorbed by the prostate cancer lesions would be 0.22 Gy for an administered activity of 3700 MBq, suggesting that the therapeutic effect of 64Cu may depend on high-linear-energy-transfer (LET) Auger electron emission rather than on the energy released by the beta radiation. Although 64Cu may have limited efficacy for large PCa lesion treatment, due to the low average absorbed radiation dose, it may be effective for the eradication of residual disease or for micro-metastasis due to the lethal effect of the Auger electrons emitted by the internalized 64Cu in the cell. Furthermore, 64Cu represents a potential tool for the radionuclide therapy of other increased metabolic copper tumors including HCC [35], glioblastoma multiforme [31] and malignant melanoma [36].

6. Conclusions

In summary, recent advances in clinical trials provide solid evidence to support the potential role of radioactive copper-64 chloride as a useful radiopharmaceutical for cancer imaging by PET. Dosimetric studies in humans demonstrated the safety of 64CuCl2. Recently, 64CuCl2 was successfully used for PET imaging of prostate cancer, bladder cancer, glioblastoma multiforme, and non-small cell lung carcinoma.
The potential theragnostic role of 64CuCl2, due to the high LET electron emission, has been reported and more clinical data are required to confirm the therapeutic efficacy of this radionuclide.

Author Contributions

Conceptualization, G.C.; methodology, G.C.; validation, G.C. and A.S.; writing—original draft preparation, G.C., A.P. and A.S.; writing—review and editing, G.C., A.P., E.G. and A.S.; supervision, G.C. and A.S.; All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Ametamey, S.M.; Honer, M.; Schubiger, P.A. Molecular imaging with PET. Chem. Rev. 2008, 108, 1501–1516. [Google Scholar] [CrossRef] [PubMed]
  2. Almedova, A.; Todorov, B.; Burdzhiev, N.; Goze, C. Copper radiopharmaceuticals for theranostic applications. Eur. J. Med. Chem. 2018, 157, 1406–1425. [Google Scholar] [CrossRef] [PubMed]
  3. Bolzati, C.; Duatti, A. The emerging value of 64Cu for molecular imaging and therapy. Q. J. Nucl. Med. Mol. Imaging 2020, 64, 329–337. [Google Scholar] [CrossRef] [PubMed]
  4. Chakravarty, R.; Chakraborty, S.; Dash, A. 64Cu2+ Ions as PET Probe: An Emerging Paradigm in Molecular Imaging of Cancer. Mol. Pharm. 2016, 13, 3601–3612. [Google Scholar] [CrossRef] [PubMed]
  5. Boschi, A.; Martini, P.; Janevik-ivanoska, E.; Duatti, A. The emerging role of copper-64 radiopharmaceuticals as cancer theranostics. Drug Discov. Today 2018, 23, 1489–1501. [Google Scholar] [CrossRef]
  6. Capriotti, G.; Duatti, A. Adding 64Curadiopharmaceuticals to the toolkit of molecular imaging. Q. J. Nucl. Med. Mol. Imaging 2020, 64, 327–328. [Google Scholar] [CrossRef]
  7. Sparks, R.; Peng, F. Positron emission tomography of altered copper metabolism for metabolic imaging and personalized therapy of prostate cancer. J. Radiol. Radiat. Ther. 2013, 1, 1015. [Google Scholar]
  8. Verwilst, P.; Sunwoo, K.; Kim, J.S. The role of copper ions in pathophysiology and fluorescent sensors for the detection thereof. Chem. Commun. 2015, 51, 5556–5571. [Google Scholar] [CrossRef]
  9. Denoyer, D.; Masaldan, S.; La Fontaine, S.; Cater, M.A. Targeting copper in cancer therapy: ‘Copper That Cancer’. Metallomics 2015, 7, 1459–1476. [Google Scholar] [CrossRef]
  10. Kaplan, J.H.; Maryon, E.B. How Mammalian Cells Acquire Copper: An Essential but Potentially Toxic Meta. Biophys. J. 2016, 110, 7–13. [Google Scholar] [CrossRef] [Green Version]
  11. Wang, H.; Chen, X. Visualization of copper metabolism by 64CuCl₂-PET. Mol. Imaging Biol. 2012, 14, 14–16. [Google Scholar] [CrossRef]
  12. Wang, F.; Jiao, P.; Qi, M.; Frezza, M.; Dou, Q.P.; Yan, B. Turning tumor-promoting copper into an anti-cancer weapon via high-throughput chemistry. Curr. Med. Chem. 2010, 17, 2685–2698. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Sproull, M.; Brechbiel, M.; Camphausen, K. Antiangiogenic therapy through copper chelation. Expert Opin. Ther. Targets 2003, 7, 405–409. [Google Scholar] [CrossRef]
  14. Raju, K.S.; Alessandri, G.; Ziche, M.; Gullino, P.M. Ceruloplasmin, copper ions, and angiogenesis. J. Natl. Cancer Inst. 1982, 69, 1183–1188. [Google Scholar]
  15. Brady, D.C.; Crowe, M.S.; Turski, M.L.; Hobbs, G.A.; Yao, X.; Chaikuad, A. Copper is required for oncogenic BRAF signalling and tumorigenesis. Nature 2014, 509, 492–496. [Google Scholar] [CrossRef] [Green Version]
  16. Safi, R.; Nelson, E.R.; Chitneni, S.K.; Franz, K.J.; George, D.J.; Zalutsky, M.R. Copper signaling axis as a target for prostate cancer therapeutics. Cancer Res. 2014, 74, 5819–5831. [Google Scholar] [CrossRef] [Green Version]
  17. Fuchs, A.G.; Lustig, E.D. Localization of tissue copper in mouse mammary tumors. Oncology 1989, 46, 183–187. [Google Scholar] [CrossRef]
  18. Canelas, H.M.; DeJorge, F.B.; Pereira, W.C.; Sallum, J. Biochemistry of cerebral tumours: Sodium, potassium, calcium, phosphorus, magnesium, copper and sulphur contents of astrocytoma, medulloblastoma and glioblastoma multiforme. J. Neurochem. 1968, 15, 1455–1461. [Google Scholar] [CrossRef]
  19. Kaiser, J.; Gullotta, F. Estimation of the copper content of astrocytomas and glioblastomas by the cuproin method. Neurochirurgia 1980, 23, 20–23. [Google Scholar]
  20. Capasso, E.; Durzu, S.; Piras, S.; Zandieh, S.; Knoll, P.; Haug, A. Role of 64CuCl2 PET/CT in staging of prostate cancer. Ann. Nucl. Med. 2015, 6, 482–488. [Google Scholar] [CrossRef]
  21. Piccardo, A.; Paparo, F.; Puntoni, M.; Righi, S.; Bottoni, G.; Bacigalupo, L. 64CuCl2 PET/CT in prostate cancer relapse. J. Nucl. Med. 2018, 59, 444–451. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Righi, S.; Ugolini, M.; Bottoni, G.; Puntoni, M.; Iacozzi, M.; Paparo, F. Biokinetic and dosimetric aspects of 64CuCl2 in human pros-tate cancer: Possible theranostic implications. Eur. J. Nucl. Med. Mol. Imaging Res. 2018, 8, 18. [Google Scholar]
  23. Paparo, F.; Peirano, A.; Matos, J.; Bacigalupo, L.; Rossi, U.; Mussetto, I. Diagnostic value of retrospectively fused (64)CuCl(2) PET/MRI in biochemical relapse of prostate cancer: Comparison with fused (18)F-Choline PET/MRI, (64)CuCl2 PET/CT, (18)F-Choline PET/CT, and mpMRI. Abdom. Radiol. 2020, 45, 3896–3906. [Google Scholar] [CrossRef]
  24. Cantiello, F.; Crocerossa, F.; Cascini, G.L.; Russo, G.I.; Ferro, M.; Cimino, S.; Lucarelli, F.; Damiano, R. 64CuCl2 PET/CT as a potential new imaging method in prostate cancer: Illusion or reality? Minerva Urol. Nephrol. 2021, 73, 668–671. [Google Scholar] [CrossRef] [PubMed]
  25. Mascia, M.; Villano, C.; De Francesco, V.; Schips, L.; Marchioni, M.; Cindolo, L. Efficacy and safety of the 64Cu(II)Cl2 PET/CT for urological malignancies: Phase IIa clinical study. Clin. Nuclear Med. 2021, 46, 443–448. [Google Scholar] [CrossRef]
  26. Panichelli, P.; Villano, C.; Cistaro, A.; Bruno, A.; Barbato, F.; Piccardo, A. Imaging of brain tumors with copper-64 chloride: Early experience and results. Cancer Biother. Radiopharm. 2016, 31, 159–167. [Google Scholar] [CrossRef]
  27. Fiz, F.; Bottoni, G.; Ugolini, M.; Righi, S.; Cirone, A.; Garganese, M.C.; Verrico, A.; Rossi, A. Diagnostic and Dosimetry Features of [64Cu]CuCl2 in High-Grade Paediatric Infltrative Gliomas. Mol. Imaging Biol. 2022. [Google Scholar] [CrossRef]
  28. García-Pérez, F.O.; Medina-Ornelas, S.S.; Barron-Barron, F.; Arrieta-Rodriguez, O. Evaluation of non-small cell lung cancer by PET/ CT with 64CuCl2: Initial experience in humans. Am. J. Nucl. Med. Mol. Imaging 2020, 10, 143–150. [Google Scholar]
  29. Guerreiro, J.F.; Alves, V.; Abrunhosa, A.J.; Paulo, A.; Gil, O.M.; Mendes, F. Radiobiological characterization of 64CuCl2 as a simple tool for prostate cancer theranostics. Molecules 2018, 23, 2944. [Google Scholar] [CrossRef] [Green Version]
  30. Pinto, C.; Bucar, S.; Alves, V.; Fonseca, A.; Abrunhosa, A.J.; da Silva, C.L. Copper-64 chloride exhibits therapeutic potential in three-dimensional cellular models of prostate cancer. Front. Mol. Biosci. 2020, 7, 609172. [Google Scholar] [CrossRef]
  31. Ferrari, C.; Niccoli, A.; Villano, C.; Giacobbi, B.; Coccetti, D.; Panichelli, P.; Giuseppe Rubini, G. Copper-64 Dichloride as Theranostic Agent for Glioblastoma Multiforme: A Preclinical Study. BioMed Res. Int. 2015, 2015, 129764. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Catalogna, G.; Talarico, C.; Dattilo, V.; Gangemi, V.; Calabria, F.; D’Antona, L.; Schenone, S.; Musumeci, F.; Bianco, C.; Perrotti, N.; et al. The SGK1 Kinase Inhibitor SI113 Sensitizes Theranostic Effects of the 64CuCl2 in Human Glioblastoma Multiforme Cells. Cell. Physiol. Biochem. 2017, 43, 108–119. [Google Scholar] [CrossRef] [Green Version]
  33. Grillo, C.A.; Reigosa, M.A.; de Mele, M.A. Does over-exposure to copper ions released from metallic copper induce cytotoxic and genotoxic effects on mammalian cells? Contraception 2010, 81, 343–349. [Google Scholar] [CrossRef]
  34. Grillo, C.A.; Reigosa, M.A.; Lorenzo de Mele, M.F. Effects of copper ions released from metallic copper on CHO-K1 cells. Mutat. Res. 2009, 672, 45–50. [Google Scholar] [CrossRef]
  35. Zhang, H.; Cai, H.; Lu, X.; Muzik, O.; Peng, F. Positron emission tomography of human hepatocellular carcinoma xenografts in mice using copper (II)-64 chloride as a tracer with copper (II)-64 chloride. Acad. Radiol. 2011, 18, 1561–1568. [Google Scholar] [CrossRef]
  36. Qin, C.; Liu, H.; Chen, K.; Hu, X.; Ma, X.; Lan, X. Theranostics of malignant melanoma with 64CuCl2. J. Nucl. Med. 2014, 55, 812–817. [Google Scholar] [CrossRef]
Jcm 12 00223 g001 550
Figure 1. Schematic representation of copper metabolism at the cellular and molecular level (64Cu as copper ions). 64Cu2+ ions are bound to plasma proteins which carry them to the external membrane, where they are reduced to Cu2+ by reductases before their uptake into cells. Reduced copper ions are then transported across the cell membrane by the human copper transporter 1 (hCTR1). In the cell, Cu2+ions are closely bound by copper chaperones (cytochrome c oxidase copper chaperone (COX17), copper chaperone for SOD1 (CCS), and antioxidant protein (ATOX1)), which deliver copper ions to the cytosol (via SOD1), mitochondria (via COX) and trans-Golgi network (via copper transporting ATPase A/B). Interestingly, glutathione (GSH) binds excess Cu2+ to prevent oxidative damage, thus protecting the cell from copper toxicity. Analogous mechanisms are carried out by metallothionein (MT). When intracellular copper is too high, hCTR1 is internalized and destroyed and copper transporting ATPase A/B (ATP7A and ATP7B) transfer from the TGN to the plasma membrane to help in the excretion of copper from the cell (adapted and modified from Michniewicz F. et al.: Copper: An Intracellular Achilles’ Heel Allowing the Targeting of Epigenetics, Kinase Pathways, and Cell Metabolism in Cancer Therapeutics. Chem Med Chem 2021, 16, 2315–2329. Copyright Wiley-VCH GmbH. Reproduced with permission).
Figure 1. Schematic representation of copper metabolism at the cellular and molecular level (64Cu as copper ions). 64Cu2+ ions are bound to plasma proteins which carry them to the external membrane, where they are reduced to Cu2+ by reductases before their uptake into cells. Reduced copper ions are then transported across the cell membrane by the human copper transporter 1 (hCTR1). In the cell, Cu2+ions are closely bound by copper chaperones (cytochrome c oxidase copper chaperone (COX17), copper chaperone for SOD1 (CCS), and antioxidant protein (ATOX1)), which deliver copper ions to the cytosol (via SOD1), mitochondria (via COX) and trans-Golgi network (via copper transporting ATPase A/B). Interestingly, glutathione (GSH) binds excess Cu2+ to prevent oxidative damage, thus protecting the cell from copper toxicity. Analogous mechanisms are carried out by metallothionein (MT). When intracellular copper is too high, hCTR1 is internalized and destroyed and copper transporting ATPase A/B (ATP7A and ATP7B) transfer from the TGN to the plasma membrane to help in the excretion of copper from the cell (adapted and modified from Michniewicz F. et al.: Copper: An Intracellular Achilles’ Heel Allowing the Targeting of Epigenetics, Kinase Pathways, and Cell Metabolism in Cancer Therapeutics. Chem Med Chem 2021, 16, 2315–2329. Copyright Wiley-VCH GmbH. Reproduced with permission).
Jcm 12 00223 g001
Jcm 12 00223 g002 550
Figure 2. 64CuCl2 PET/CT in prostate cancer relapse. (A) 64CuCl2 biodistribution with high activity in the liver, and kidneys and lesser in the bowel. 64CuCl2 PET/CT image of pelvis from a old man treated with radical prostatectomy with rising PSA level demonstrated copper-avid recurrence in vescicourethral anastomosis (B) and nodes (C). Adapted from ref. [21] with (This research was originally published in JNM. A. Piccardo et al. 64CuCl2 PET/CT in prostate cancer relapse. J. Nucl. Med. 2018, 59, 444–451. ©SNMMI).
Figure 2. 64CuCl2 PET/CT in prostate cancer relapse. (A) 64CuCl2 biodistribution with high activity in the liver, and kidneys and lesser in the bowel. 64CuCl2 PET/CT image of pelvis from a old man treated with radical prostatectomy with rising PSA level demonstrated copper-avid recurrence in vescicourethral anastomosis (B) and nodes (C). Adapted from ref. [21] with (This research was originally published in JNM. A. Piccardo et al. 64CuCl2 PET/CT in prostate cancer relapse. J. Nucl. Med. 2018, 59, 444–451. ©SNMMI).
Jcm 12 00223 g002
Jcm 12 00223 g003 550
Figure 3. Brain 64CuCl2 PET/CT scan of a cerebral glioblastoma collected at 1 h post injection (injected activity, 13 MBq/kg). Adapted from ref. [26] with permission of Panichelli P et al. Imaging of brain tumors with copper-64 chloride: Early experience and results. Cancer Biother. Radiopharm. 2016, 31, 159–167.
Figure 3. Brain 64CuCl2 PET/CT scan of a cerebral glioblastoma collected at 1 h post injection (injected activity, 13 MBq/kg). Adapted from ref. [26] with permission of Panichelli P et al. Imaging of brain tumors with copper-64 chloride: Early experience and results. Cancer Biother. Radiopharm. 2016, 31, 159–167.
Jcm 12 00223 g003
Table
Table 1. Decay characteristics and properties of copper radioisotopes.
Table 1. Decay characteristics and properties of copper radioisotopes.
60Cu61Cu62Cu64Cu67Cu
Production reaction
(Source)		60Ni(p,n)60Cu (Cyclotron)61Ni(p,n)61Cu (Cyclotron)62Zn/62Cu (Generator) 62Ni(p,n)62Cu (Cyclotron)natZn(p,xn)64Cu (Reactor)
63Cu(n,g)64Cu (Reactor)
64Ni(p,n)64Cu (Cyclotron)		67Zn(n,p)67Cu
(Reactor)
68Zn(p,2p)67Cu (Cyclotron)
70Zn(p,a)67Cu (Cyclotron)
Half-life23.4 min3.3 h9.7 min12.7 h62.0 h
Decay β− MeV (%)---0.573 (38.4)0.395 (45)
0.484 (35)
0.577 (20)
Decay β+ MeV (%)3.92 (6)
3.00 (18)
2.00 (69)		1.22 (60)2.91 (6)0.655 (17.8)-
EC7.4%40%2%43.8%-
γ MeV (%)0.511 (186)
0.85 (15)
1.33 (80)
1.76 (52)
2.13 (6)		0.284 (12)
0.38 (3)
0.511 (120)		0.511 (194)0.511 (35.6)
1.35 (0.6)		0.184 (40)
Clinical UseImagingImagingImagingImaging and therapyTherapy
MeV: megaelettronvolt.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Capriotti, G.; Piccardo, A.; Giovannelli, E.; Signore, A. Targeting Copper in Cancer Imaging and Therapy: A New Theragnostic Agent. J. Clin. Med. 2023, 12, 223. https://doi.org/10.3390/jcm12010223

AMA Style

Capriotti G, Piccardo A, Giovannelli E, Signore A. Targeting Copper in Cancer Imaging and Therapy: A New Theragnostic Agent. Journal of Clinical Medicine. 2023; 12(1):223. https://doi.org/10.3390/jcm12010223

Chicago/Turabian Style

Capriotti, Gabriela, Arnoldo Piccardo, Elena Giovannelli, and Alberto Signore. 2023. "Targeting Copper in Cancer Imaging and Therapy: A New Theragnostic Agent" Journal of Clinical Medicine 12, no. 1: 223. https://doi.org/10.3390/jcm12010223

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop